Seralutinib
- Generic Name
- Seralutinib
- Drug Type
- Small Molecule
- Chemical Formula
- C27H27N5O3
- CAS Number
- 1619931-27-9
- Unique Ingredient Identifier
- 3P63ZTE3OY
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
Phase 3
Recruiting
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Device: Gereic Dry Powder Inhaler
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- GB002, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT06274801
- Locations
- 🇩🇰
Aarhus Universiteshospital, Aarhus, Denmark
🇸🇬National University Heart Centre, Singapore, Singapore
🇪🇸Hospital Clinic I Provincial, Barcelona, Spain
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
Phase 3
Recruiting
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- GB002, Inc.
- Target Recruit Count
- 350
- Registration Number
- NCT05934526
- Locations
- 🇨🇴
Fundación Neumologica Colombiana, Bogotá, Colombia
🇬🇷ATTIKON University Hospital, 2nd Critical Care Department, Athens, Greece
🇬🇷Onassis Cardiac Surgery Center, Kallithéa, Greece
Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension
Phase 1
Completed
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- First Posted Date
- 2019-04-25
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03926793
- Locations
- 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Phase 1A Safety Trial of Inhaled PK10571 (GB002)
Phase 1
Completed
- Conditions
- Safety Issues
- Interventions
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT03473236
- Locations
- 🇺🇸
Phase 1 Unit, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath